



Founded in 1989, LVL Médical is now a standard setter in the In-home Medical Assistance market. In order to meet the growing requirements of its patients and prescribing doctors, the Group, which originally specialised in respiratory assistance, has progressively extended its business activities to perfusion, nutrition and insulin therapy services, as well as to nursing care, in-home intensive care and nursing units (Germany). LVL Médical takes care of over 50,000 patients every day.

LVL Medical Group  
Investor relations  
Tel. + 33 (0)4 26 68 68 68  
actionnaires@lvl-medical.fr  
www.lvl-medical.com

www.lvl-medical.com  
LVL Médical is quoted on  
Euronext Paris - Compartment B  
and has only been available for  
long-only deferred settlement  
since May 26th 2010.

ISIN FR0000054686  
Reuters LVL.M.PA  
Bloomberg LVL  
Indices:  
SBF 250  
CAC Small 90

**LVL**  
**LISTED**  
**NYSE**  
**EURONEXT**

## LVL Médical Group consolidates its strong growth rate Consolidated 2009-2010 revenues: + 14.4%

Lyon, October 20<sup>th</sup> 2010 – LVL Médical Group announces consolidated revenues of €155.7 million for the 2009-2010 financial year, compared with €136.1 million for the previous financial year, i.e. a growth rate of 14.4%. On a like-for-like basis, revenues amounted to €152 million, i.e. an increase of 11.7%.

Rev. ( m )	France	Germany	Revenues	Changes in the scope of consolidation	LVL Médical Group
Business Activities	In-home medical assistance	Intensive and outpatient care	On a like-for-like basis (previous comparable)	Acquisitions (*)	<b>Total Rev.</b>
2008-2009	86.5	49.6	136.1	-	136.1
<b>2009-2010</b>	96.8	55.2	<b>152.0</b>	3.7	<b>155.7</b>
Increase	12%	11.2%	<b>11.7%</b>	2.7%	<b>14.4%</b>

(\*) Acquisitions in Germany that were made during the financial year: AKS, Filius, Air Vital

### FRANCE

Revenues in France amounted to 96.8 million as at 30/09/2010, up 12% on a like-for-like basis compared with the previous financial year. Excluding the impact of lower rates on the respiratory business, that growth would have been 13.9%. This trend reflects strong growth of the Group's strategic businesses.

The respiratory assistance segment reported growth of 7%, with revenues of 59.2 million as at 30.09.2010.

The Perfusion, Nutrition and Insulin Therapy (PNI) businesses grew very significantly, by 22%, reaching annual revenues of 37.6 million as at 30.09.2010.

These performances reflect the appropriateness of the LVL Médical Group model and of its sound strategic choices.

### GERMANY

The revenues generated by the in-home nursing care facilities and the intensive care units continued to ramp up, reaching 58.9 million as at 30.09.2010, compared with 49.6 million as at 30.09.2008, i.e. a growth rate of 18.7%. On a like-for-like basis, the divisions' growth rate worked out at 11.2%.

LVL Médical Group has thus consolidated its leading position in this market. The acquisitions made during the financial year and their successful integration show the Group's ability to combine strong organic growth with external growth that is both controlled and profitable.

### TENDER OFFER

The tender offer that LVL Médical Group launched in September 2010 as part of the company's share buy-back programme was a resounding success.

The transaction involved a maximum of 698,759 shares, i.e. 6% of the company's share capital, at a price of 20 per share. 3,066,420 shares in LVL Médical Group were tendered under the offer, i.e. around four times more shares than the number covered by the tender.

### OUTLOOK

The Group intends to maintain a sustainable and profitable growth rate both organically and through external growth opportunities.

### NEXT ANNOUNCEMENT

LVL Médical Group will publish its annual results for the financial year ending on September 30<sup>th</sup> 2010 on December 15<sup>th</sup>, after the Stock Market close.